Phenotype Restricted Genome-Wide Association Study Using a Gene-Centric Approach Identifies Three Low-Risk Neuroblastoma Susceptibility Loci

Neuroblastoma is a malignant neoplasm of the developing sympathetic nervous system that is notable for its phenotypic diversity. High-risk patients typically have widely disseminated disease at diagnosis and a poor survival probability, but low-risk patients frequently have localized tumors that are almost always cured with little or no chemotherapy. Our genome-wide association study (GWAS) has identified common variants within FLJ22536, BARD1, and LMO1 as significantly associated with neuroblastoma and more robustly associated with high-risk disease. Here we show that a GWAS focused on low-risk cases identified SNPs within DUSP12 at 1q23.3 (P = 2.07×10−6), DDX4 and IL31RA both at 5q11.2 (P = 2.94×10−6 and 6.54×10−7 respectively), and HSD17B12 at 11p11.2 (P = 4.20×10−7) as being associated with the less aggressive form of the disease. These data demonstrate the importance of robust phenotypic data in GWAS analyses and identify additional susceptibility variants for neuroblastoma.

[1]  Nazneen Rahman,et al.  Integrative genomics identifies LMO1 as a neuroblastoma oncogene , 2011, Nature.

[2]  Mary Goldman,et al.  The UCSC Genome Browser database: update 2011 , 2010, Nucleic Acids Res..

[3]  J. Maris Recent advances in neuroblastoma. , 2010, The New England journal of medicine.

[4]  Sharon J. Diskin,et al.  Copy number variation at 1q21.1 associated with neuroblastoma , 2009, Nature.

[5]  J Khan,et al.  International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee , 2009, British Journal of Cancer.

[6]  Nazneen Rahman,et al.  Common variations in BARD1 influence susceptibility to high-risk neuroblastoma , 2009, Nature Genetics.

[7]  Nazneen Rahman,et al.  Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. , 2008, The New England journal of medicine.

[8]  Giorgio Valle,et al.  The Gene Ontology project in 2008 , 2007, Nucleic Acids Res..

[9]  Jill P. Mesirov,et al.  GSEA-P: a desktop application for Gene Set Enrichment Analysis , 2007, Bioinform..

[10]  J. Khan,et al.  181 INVITED International consensus for neuroblastoma molecular diagnostics: report from the international neuroblastoma risk grouping (INRG) biology committee , 2007 .

[11]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[12]  M. Newton,et al.  Random-set methods identify distinct aspects of the enrichment signal in gene-set analysis , 2007, 0708.4350.

[13]  Terrence S. Furey,et al.  The UCSC Genome Browser Database: update 2006 , 2005, Nucleic Acids Res..

[14]  Jelle J. Goeman,et al.  A global test for groups of genes: testing association with a clinical outcome , 2004, Bioinform..

[15]  K K Matthay,et al.  The International Neuroblastoma Pathology Classification (the Shimada system) , 1999, Cancer.

[16]  F. Berthold,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.

[17]  A T Look,et al.  Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[19]  N. Breslow,et al.  Statistical estimation of prognosis for children with neuroblastoma. , 1971, Cancer research.